Systematic review / meta-analysisHuman
The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials
BMC infectious diseases, 2016 Sep 15. Liu F, Wang HM, Wang T and 2 others.
Study type
Systematic review / meta-analysis
Subjects
Human participants (PubMed MeSH: Humans)
Journal
BMC infectious diseases
Published
2016 Sep 15
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
APACHECytokinesHumansImmunologic FactorsIntensive Care UnitsInterleukin-10Interleukin-6Length of StayLymphocyte SubsetsMultiple Organ FailureRandomized Controlled Trials as TopicRespiration, Artificial
Other papers on Thymosin α-1
Randomized controlled trial · 2013
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Journal article · 2020Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page